A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.

Trial Profile

A Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin, Administered Using Stereotactic Injection to the Striatum of Patients With Bilateral, Idiopathic Parkinson's Disease.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Parkinson's disease gene therapy (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Oxford BioMedica
  • Most Recent Events

    • 17 Mar 2017 According to an Oxford BioMedica media release, follow-up data from the study has been presented in May 2016 at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT).
    • 05 May 2015 According to an Oxford BioMedica media release, data from this trial were presented at the American Association of Neurological Surgeons (AANS) conference.
    • 20 Jun 2013 New source identified and integrated: ClinicalTrials.gov record NCT01856439.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top